Literature DB >> 12349825

Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration.

A H Thomson, G Shankland, C Clareburt, S Binning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12349825     DOI： 10.1007/s00134-002-1340-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

Review 1.  Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.

Authors:  A Vermes; H J Guchelaar; J Dankert
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.

Authors:  A W Kelman; B Whiting; S M Bryson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

3.  5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration.

Authors:  T H Ittel; U F Legler; A Polak; W M Glöckner; H G Sieberth
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

4.  Elimination of flucytosine by continuous hemofiltration.

Authors:  A H Lau; N O Kronfol
Journal:  Am J Nephrol       Date:  1995       Impact factor: 3.754
  4 in total
  2 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 2.  Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?

Authors:  Daniela Baracaldo-Santamaría; Juan David Cala-Garcia; Germán José Medina-Rincón; Luis Carlos Rojas-Rodriguez; Carlos-Alberto Calderon-Ospina
Journal:  Antibiotics (Basel)       Date:  2022-05-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.